These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Mann J; Gershon S Life Sci; 1980 Mar; 26(11):877-82. PubMed ID: 6768943 [No Abstract] [Full Text] [Related]
4. The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression. Mann JJ; Frances A; Kaplan RD; Kocsis J; Peselow ED; Gershon S J Clin Psychopharmacol; 1982 Feb; 2(1):54-7. PubMed ID: 6802883 [No Abstract] [Full Text] [Related]
5. Brief information on an early phase-II study with deprenyl in demented patients. Martini E; Pataky I; Szilágyi K; Venter V Pharmacopsychiatry; 1987 Nov; 20(6):256-7. PubMed ID: 3124143 [TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome. Trebini F; Daniele D; Gillio S; Scarzella L Acta Neurol (Napoli); 1985 Oct; 7(5):432-9. PubMed ID: 3933283 [No Abstract] [Full Text] [Related]
7. MAO-B-Inhibitor selegiline (R-(-)-deprenyl). A new therapeutic concept in the treatment of Parkinson's disease. Proceedings of the international symposium. Berlin, January 23-25, 1987. J Neural Transm Suppl; 1987; 25():1-197. PubMed ID: 3123595 [No Abstract] [Full Text] [Related]
10. Deprenyl for the treatment of early Parkinson's disease. N Engl J Med; 1990 May; 322(21):1526-8. PubMed ID: 2110624 [No Abstract] [Full Text] [Related]
11. L-deprenyl in the treatment of Parkinson's disease. Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993 [TBL] [Abstract][Full Text] [Related]
12. Deprenyl and the progression of Parkinson's disease. Science; 1990 Jul; 249(4966):303-4. PubMed ID: 2115691 [No Abstract] [Full Text] [Related]
13. Differential efficacy of L-deprenyl, a selective MAO type-B inhibitor, in endogenous and nonendogenous depression. Mann JJ; Frances A; Peselow ED; Gershon S Psychopharmacol Bull; 1982 Oct; 18(4):182-4. PubMed ID: 6818606 [No Abstract] [Full Text] [Related]
14. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease. Rinne UK J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601 [TBL] [Abstract][Full Text] [Related]
15. [The use of L-deprenyl in Parkinson's disease]. Zhonghua Yi Xue Za Zhi; 1983 Mar; 63(3):147-9. PubMed ID: 6409375 [No Abstract] [Full Text] [Related]
16. A placebo-controlled trial of L-deprenyl in atypical depression. McGrath PJ; Stewart JW; Harrison W; Wager S; Nunes EN; Quitkin FM Psychopharmacol Bull; 1989; 25(1):63-7. PubMed ID: 2505303 [No Abstract] [Full Text] [Related]
17. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor. Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358 [No Abstract] [Full Text] [Related]
18. [Treatment of extra-puerperal galactorrhea with the MAO-B inhibitor selegiline]. Sas M; Godó G; Koleszár G Orv Hetil; 1986 Jun; 127(25):1507-8, 1511. PubMed ID: 3088511 [No Abstract] [Full Text] [Related]
19. REM changes in narcolepsy with selegiline. Reinish LW; MacFarlane JG; Sandor P; Shapiro CM Sleep; 1995 Jun; 18(5):362-7. PubMed ID: 7676170 [TBL] [Abstract][Full Text] [Related]
20. Anti-depressant potentiation of 5-hydroxytryptophan by L-deprenyl, an MAO "type B" inhibitor. Mendlewicz J; Youdim MB J Neural Transm; 1978; 43(3-4):279-86. PubMed ID: 745020 [No Abstract] [Full Text] [Related] [Next] [New Search]